Press Release

CalciMedica Names Life Science Veteran to Its Board of Directors

LA JOLLA, CA, March 26, 2019 /PRNewswire/ — CalciMedica, a clinical-stage biopharmaceutical company developing CM4620, a novel small molecule compound for acute pancreatitis, announced that A. Rachel Leheny, Ph.D., has joined its Board of Directors. Dr. Leheny is a Founding Managing Director for Valence Advantage Life Sciences, a life science venture firm based in New …

CalciMedica Names Life Science Veteran to Its Board of Directors Read More »

CalciMedica, Inc. to Present Study Population Profile from Its Initial Patient Study of Its CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at International Conference

LA JOLLA, CA, March 19, 2019 /PRNewswire/ — Physicians from several study sites involved in CalciMedica’s initial acute pancreatitis clinical study of its CRAC channel inhibitor CM4620 (NCT03401109) and CalciMedica, Inc., presented a poster today at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM) being held in Brussels on March 19-22. The …

CalciMedica, Inc. to Present Study Population Profile from Its Initial Patient Study of Its CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at International Conference Read More »

CalciMedica Names Two Senior Executives to Its Board of Directors

LA JOLLA, CA, May 1, 2018 /PRNewswire/ — CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently Chief Medical Officer of La Jolla Pharmaceuticals Company (NASDAQ: LJPC), and Christopher Krueger, JD, MBA, a co-founder and Chief Business Officer of Escalier Biosciences. The two new Board members bring …

CalciMedica Names Two Senior Executives to Its Board of Directors Read More »

Research Collaboration Between the San Francisco VA, UCSF and CalciMedica, Inc. to Present Results on CRAC Channel Inhibitors in a Stroke Model at International Conference

LA JOLLA, CA, January 24, 2018 /PRNewswire/ — Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a poster at the International Stroke Conference being held in Los Angeles that describes the use of one of CalciMedica’s calcium release-activated calcium (CRAC) channel inhibitors in an experimental model of …

Research Collaboration Between the San Francisco VA, UCSF and CalciMedica, Inc. to Present Results on CRAC Channel Inhibitors in a Stroke Model at International Conference Read More »

CalciMedica Receives Fast-Track Designation for CM4620, A Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis

PATIENT STUDIES EXPECTED TO BEGIN IN EARLY 2018 LA JOLLA, Calif., May 24, 2017 /PRNewswire/ — Privately-held CalciMedica, Inc., announced today that it received Fast-track designation from the U.S. Food and Drug Administration (US FDA) for its lead clinical compound, CM4620, a novel, calcium release-activated calcium (CRAC) channel inhibitor, for the treatment of acute pancreatitis. …

CalciMedica Receives Fast-Track Designation for CM4620, A Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis Read More »

CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor

LA JOLLA, Calif., January 5, 2017 /PRNewswire/ — Privately-held CalciMedica, Inc., announced that it started Phase 1 safety studies in healthy volunteers of a novel calcium release-activated calcium (CRAC) channel inhibitor, CM4620, intended to treat acute pancreatitis. Acute pancreatitis, sudden painful inflammation of the pancreas, is typically a mild disorder, but can be very serious. …

CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor Read More »

Scroll to Top